UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biopharmaceutical enterprise headquartered in Princeton, New Jersey. The company focuses on the development and commercialization of innovative therapies for urological cancers and conditions. Its proprietary RTGel technology platform enables the sustained release of pharmaceutical compounds directly into the urinary tract. Principal revenue is derived through commercial pharmaceutical sales and research collaboration agreements. UroGen Pharma Ltd is publicly listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in UroGen Pharma.
- Legal name
- UroGen Pharma Ltd
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding UroGen Pharma
- DNB Bioteknologi — DNB · 1.24 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)